

Report to:	Public Board of Directors	Agenda item:	15
Date of Meeting:	26 February 2020		

Title of Report:	Management Board Update Report
Status:	For Information
Sponsor:	James Scott, Chief Executive
Author:	Adewale Kadiri, Head of Corporate Governance
Appendices	None

Purpose

This report provides an update from the Management Board meeting held on 22 January 2020.

Background

The Board of Directors has constituted the Management Board as the highest level executive body responsible for delivery of the operational objectives of the Trust.

Business Undertaken

Clinical Services Strategy

The draft strategy was presented to Management Board for discussion and feedback ahead of a further and final presentation in February. The changes that had been made to this version included the provision of further information around sustainability, and a more overt reference to the Trust's ambition to empower patients to own their care.

Private Patient Strategy

Management Board supported the overall thrust of this draft strategy.

Business Cases

Management Board agreed that the Heart Failure Business Case would be added to the prioritisation list.

Operational Performance Report

The Trust's RTT performance was 2.3% above the national performance, and gastroenterology had improved to 92.3%. Appraisal compliance remains problematic and is being addressed with the teams.

Divisional Business Plans

Management Board received presentations from the three clinical divisions on their business plans for 2020/21. The Head of Business Development offered to provide support in delivering some of the projects set out.

Strategic Development Group

The Commercial Director announced the formation of a new Strategic Development Group which will replace the Strategic Assurance Committee and the Redevelopment Board. With effect from 1 February 2020, the Commercial Directorate will be renamed Strategy Directorate.

Policy update

The Head of Corporate Governance reminded Management Board members of the need to keep the policies and procedures for which they were responsible up to date. Administrative support is available to assist teams in this regard.

Other standing/regular agenda items were considered including the Q3 Business Plan Quarterly Review and the Non-Clinical Incidents and Litigation Report

Key Risks and their impact on the Organisation

The Director of Nursing & Midwifery presented the status of the current risks on the Risk Register. The Deputy Director of Finance is to review the financial risk in view of next year's outlook.

Key Decisions

As listed above.

Exceptions and Challenges

The Management Board was able to undertake its business without any gaps in information.

Governance and Other Business

As listed above.

Future Business

The key focus of the Management Board over the next 3 months will be:

- Operational Performance
- Finance
- Winter pressures
- QIPP Programme

Recommendations

The Board of Directors is asked to note the report.